WO2026114911 - OREXIN 2 RECEPTOR AGONISTS
National phase entry is expected:
Publication Number
WO/2026/114911
Publication Date
04.06.2026
International Application No.
PCT/EP2025/084278
International Filing Date
26.11.2025
Title **
[English]
OREXIN 2 RECEPTOR AGONISTS
[French]
AGONISTES DU RÉCEPTEUR 2 DE L'ORÉXINE
Applicants **
H. LUNDBECK A/S
Inventors
JUHL, Karsten
ASCIC, Erhad
YU, Wanwan
ANDERSEN, Thomas, Leegaard
BÆK, Michael
MIKKELSEN, Gitte, Kobberøe
ARNOLD, Andreas, Michael
HANSEN, Anders, Højgaard
LINDOVSKÁ, Petra
KERÄNEN, Henrik, Juhani
PLANAS PADRÓS, Ferran
Priority Data
24215810.3
27.11.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3298 | |
| EPO | Filing, Examination, Granting | 14310 | |
| Japan | Filing, Examination, Granting | 2246 | |
| South Korea | Filing, Examination, Granting | 2259 | |
| USA | Filing, Examination, Granting | 6240 |
Total:
28,353
Contact Us
Abstract[English]
The present invention relates to novel compounds of general formula (I) which are Orexin 2 receptor agonists.[French]
La présente invention concerne de nouveaux composés de formule générale (I) qui sont des agonistes du récepteur 2 de l'oréxine.